niacinamide has been researched along with Vomiting in 13 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was performed to identify clinical predictors for better survival in patients with advanced hepatocellular carcinoma (HCC) under sorafenib treatment." | 7.79 | Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. ( Ganten, TM; Gotthardt, D; Jaeger, D; Koehler, C; Koschny, R; Stremmel, W, 2013) |
| "To study the efficacy of tetracycline (or doxycycline) and nicotinamide in the treatment of less extensive bullous pemphigoid." | 7.70 | Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore. ( Goon, AT; Khoo, LS; Tan, SH; Tan, T, 2000) |
| "This study was performed to identify clinical predictors for better survival in patients with advanced hepatocellular carcinoma (HCC) under sorafenib treatment." | 3.79 | Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. ( Ganten, TM; Gotthardt, D; Jaeger, D; Koehler, C; Koschny, R; Stremmel, W, 2013) |
| "Pellagra is a nutritional disease caused by the deficiency of niacin." | 3.79 | Pellagra revealing a congenital duodenal diaphragm in an adult. ( Ahmed, S; Farah, J; Haykel, B; Houcine, M; Khouloud, B; Yacine, BS; Zoubeir, BS, 2013) |
| "To study the efficacy of tetracycline (or doxycycline) and nicotinamide in the treatment of less extensive bullous pemphigoid." | 3.70 | Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore. ( Goon, AT; Khoo, LS; Tan, SH; Tan, T, 2000) |
| " Frequently occurring motesanib-related adverse events included diarrhea (n = 19), nausea (n = 18), vomiting (n = 13), and fatigue (n = 12), which were mostly of worst grade < 3." | 2.76 | Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. ( Adewoye, AH; Desai, J; Johnson, J; Kotasek, D; McCoy, S; Price, T; Siu, LL; Sun, YN; Tebbutt, N; Welch, S, 2011) |
| "Full pharmacokinetic profiles of nicotinamide concentrations in plasma were analyzed repeatedly in 15 patients to determine the inter- and intra-patient variability in peak plasma concentrations and the optimum times for administering nicotinamide as a radiosensitizer." | 2.69 | Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. ( Bernier, J; Bieri, S; Bolla, M; Denekamp, J; Dennis, MF; Hagen, F; Kocagöncü, O; Rojas, A; Stratford, MR, 1998) |
| "Diarrhea was the most common GI event." | 2.50 | Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. ( Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M, 2014) |
| " A next group of 87 patients received 60 mg/kg nicotinamide in combination with domperidone." | 1.31 | Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy. ( Bussink, J; Folkes, LK; Kaanders, JH; Stratford, MR; van der Kogel, AJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santoni, M | 1 |
| Conti, A | 1 |
| De Giorgi, U | 1 |
| Iacovelli, R | 1 |
| Pantano, F | 1 |
| Burattini, L | 1 |
| Muzzonigro, G | 1 |
| Berardi, R | 1 |
| Santini, D | 1 |
| Cascinu, S | 1 |
| De Savi, C | 1 |
| Cox, RJ | 1 |
| Warner, DJ | 1 |
| Cook, AR | 1 |
| Dickinson, MR | 1 |
| McDonough, A | 1 |
| Morrill, LC | 1 |
| Parker, B | 1 |
| Andrews, G | 1 |
| Young, SS | 1 |
| Gilmour, PS | 1 |
| Riley, R | 1 |
| Dearman, MS | 1 |
| Kotasek, D | 1 |
| Tebbutt, N | 1 |
| Desai, J | 1 |
| Welch, S | 1 |
| Siu, LL | 1 |
| McCoy, S | 1 |
| Sun, YN | 1 |
| Johnson, J | 1 |
| Adewoye, AH | 1 |
| Price, T | 1 |
| Koschny, R | 1 |
| Gotthardt, D | 1 |
| Koehler, C | 1 |
| Jaeger, D | 1 |
| Stremmel, W | 1 |
| Ganten, TM | 1 |
| Khouloud, B | 1 |
| Haykel, B | 1 |
| Ahmed, S | 1 |
| Houcine, M | 1 |
| Yacine, BS | 1 |
| Farah, J | 1 |
| Zoubeir, BS | 1 |
| Bussink, J | 1 |
| Stratford, MR | 3 |
| van der Kogel, AJ | 1 |
| Folkes, LK | 1 |
| Kaanders, JH | 1 |
| Ruddock, MW | 2 |
| Hirst, DG | 2 |
| Saunders, MI | 1 |
| Hoskin, PJ | 1 |
| Pigott, K | 1 |
| Powell, ME | 1 |
| Goodchild, K | 1 |
| Dische, S | 1 |
| Denekamp, J | 2 |
| Dennis, MF | 2 |
| Rojas, AM | 1 |
| Bernier, J | 1 |
| Bieri, S | 1 |
| Hagen, F | 1 |
| Kocagöncü, O | 1 |
| Bolla, M | 1 |
| Rojas, A | 1 |
| Burns, DM | 1 |
| Murphy, LE | 1 |
| O'Rourke, MG | 1 |
| Goon, AT | 1 |
| Tan, SH | 1 |
| Khoo, LS | 1 |
| Tan, T | 1 |
| Burnouf, C | 1 |
| Auclair, E | 1 |
| Avenel, N | 1 |
| Bertin, B | 1 |
| Bigot, C | 1 |
| Calvet, A | 1 |
| Chan, K | 1 |
| Durand, C | 1 |
| Fasquelle, V | 1 |
| Féru, F | 1 |
| Gilbertsen, R | 1 |
| Jacobelli, H | 1 |
| Kebsi, A | 1 |
| Lallier, E | 1 |
| Maignel, J | 1 |
| Martin, B | 1 |
| Milano, S | 1 |
| Ouagued, M | 1 |
| Pascal, Y | 1 |
| Pruniaux, MP | 1 |
| Puaud, J | 1 |
| Rocher, MN | 1 |
| Terrasse, C | 1 |
| Wrigglesworth, R | 1 |
| Doherty, AM | 1 |
| Grillo, G | 1 |
| Luvarà, A | 1 |
| Rovere, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors[NCT01235416] | Phase 1 | 57 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for niacinamide and Vomiting
| Article | Year |
|---|---|
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; | 2014 |
3 trials available for niacinamide and Vomiting
| Article | Year |
|---|---|
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Deoxy | 2011 |
Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study.
Topics: Administration, Oral; Aerosols; Antiemetics; Carbon Dioxide; Disease-Free Survival; Dose Fractionati | 1997 |
Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.
Topics: Administration, Oral; Area Under Curve; Carbon Dioxide; Carcinoma; Carcinoma, Non-Small-Cell Lung; C | 1998 |
9 other studies available for niacinamide and Vomiting
| Article | Year |
|---|---|
Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.
Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents; Benzamides; Dogs; Ferrets; Humans; Li | 2014 |
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; Follow-Up S | 2013 |
Pellagra revealing a congenital duodenal diaphragm in an adult.
Topics: Adult; Diaphragm; Duodenal Obstruction; Female; Humans; Hyperpigmentation; Malnutrition; Niacinamide | 2013 |
Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma; Domperidone; Dose Fractionation, Radiatio | 2002 |
Metabolites of the radiosensitizer nicotinamide are unlikely to contribute to the degree of emesis observed with the parent drug.
Topics: Animals; Arteries; Ileum; Isotonic Solutions; Male; Niacinamide; Peristalsis; Radiation-Sensitizing | 2007 |
The effect of nicotinamide on spontaneous and induced activity in smooth and skeletal muscle.
Topics: Animals; Anura; Culture Techniques; Dose-Response Relationship, Drug; Gastrointestinal Motility; Ile | 2000 |
Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore.
Topics: Aged; Anti-Bacterial Agents; Complement C3; Diarrhea; Doxycycline; Drug Combinations; Female; Fluore | 2000 |
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Anti-Asthmatic Ag | 2000 |
[Metoclopramide does not influence urinary elimination of N-methylnicotinamide and 5-OH-indoleacetic acid].
Topics: Adult; Amides; Benzoates; Female; Humans; Indoleacetic Acids; Injections, Intramuscular; Nausea; Nia | 1968 |